-
Mashup Score: 27
SNMMI 2025, Prostate Cancer, Radioimmunotherapy Agent, CD46-Targeted Antibody-Drug Conjugate, CD46-Targeted Antibody-Drug Conjugate and a Radioimmunotherapy Agent for the Treatment of Prostate Cancer, anti-CD46 targeted antibody, YS5, [225Ac]Macropa-PEG4-YS5, [89Zr]DFO-YS5, 225Ac-YS5, Actinium-225.
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
A combination of a CD46-targeted antibody-drug conjugate and a radioimmunotherapy agent for the treatment of #ProstateCancer. Presentation by @anilbidkar1 @UCSF. #SNMMI25 written coverage by @RKSayyid @USC > https://t.co/HoS4ZDJaRq @SNM_MI #SNMMI2025 https://t.co/G0st92ko5l